A.I. "Can ctc analysis test immunotheropy respose?"9 Jun 2025 11:11
AI Overview
Yes, CTC (circulating tumor cell) analysis can be used to assess immunotherapy response, particularly in the context of PD-L1 expression. By analyzing CTCs, researchers can monitor changes in PD-L1 levels on circulating tumor cells, which can be a marker of response to PD-1/PD-L1 inhibitor therapy.
Here's how CTC analysis is used to assess immunotherapy response:
PD-L1 Expression:
PD-L1 is a protein expressed on tumor cells that can help them evade immune attack. Measuring PD-L1 expression on CTCs can provide insights into the tumor's response to immunotherapy, as PD-L1 is a key target for checkpoint inhibitors.
Dynamic Changes:
Monitoring changes in the number and PD-L1 expression levels of CTCs during treatment can help track the effectiveness of immunotherapy. For example, a reduction in PD-L1-high CTCs might indicate a beneficial response, while increases might suggest disease progression.
Correlation with Clinical Outcomes:
Studies have shown that CTC PD-L1 expression can correlate with progression-free survival (PFS) and overall survival (OS) in patients receiving PD-1/PD-L1 inhibitor therapy.
Liquid Biopsy:
CTC analysis is a type of liquid biopsy, allowing for real-time monitoring of tumor cells without invasive procedures.
Potential Biomarker:
CTC PD-L1 expression has been proposed as a potential biomarker for immunotherapy response, and its integration into diagnostic and therapeutic algorithms may be warranted.
In summary, CTC analysis, particularly the assessment of PD-L1 expression, can provide valuable information about the response to immunotherapy by allowing for real-time monitoring of tumor cell activity and changes in PD-L1 expression.
=================================
Maybe Angle's sales team need major changes.
Their lab work seems excellent but I wonder if their sales team could sell a bottle of water to a person dying of thirst?
Or maybe Newland is the problem?
All IMHO.
Sign In
Follow the stocks
